Published in
Springer, Breast Cancer Research and Treatment, 1(178), p. 121-133, 2019
DOI: 10.1007/s10549-019-05360-3
Links
Tools
A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer
Journal article published in 2019 by
Vandana G. Abramson 
,
Mafalda Oliveira,
Andrés Cervantes,
Hans Wildiers,
Manish R. Patel,
Todd M. Bauer ,
Philippe L. Bedard ,
Carlos Becerra,
Stephen Richey,
Michael C. Wei,
Eric Reyner,
John Bond,
Na Cui,
Timothy R. Wilson,
Heather M. Moore
and other authors.
,
Mafalda Oliveira,
Andrés Cervantes,
Hans Wildiers,
Manish R. Patel,
Todd M. Bauer ,
Philippe L. Bedard ,
Carlos Becerra,
Stephen Richey,
Michael C. Wei,
Eric Reyner,
John Bond,
Na Cui,
Timothy R. Wilson,
Heather M. Moore
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 